Neogen (NASDAQ:NEOG) Stock Rating Cut to Buy at Wall Street Zen

by · The Cerbat Gem

Wall Street Zen downgraded shares of Neogen (NASDAQ:NEOG – Free Report) from a strong-buy rating to a buy rating in a research note issued to investors on Sunday morning,Wall Street Zen reports.

Several other brokerages also recently issued reports on NEOG. Guggenheim reissued a “buy” rating and issued a $14.00 price objective (up from $12.00) on shares of Neogen in a research note on Wednesday, September 30th. Piper Sandler upgraded Neogen from a “neutral” rating to an “overweight” rating and raised their price objective for the stock from $13.00 to $14.00 in a research report on Wednesday, August 26th. Finally, Weiss Ratings raised Neogen from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, August 7th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $12.67.

Get Our Latest Report on Neogen

Neogen Price Performance

NEOG opened at $11.85 on Friday. The stock has a fifty day moving average of $12.12 and a 200-day moving average of $10.31. The firm has a market capitalization of $2.59 billion, a P/E ratio of -47.40, a PEG ratio of 4.44 and a beta of 1.79. Neogen has a 12-month low of $5.37 and a 12-month high of $14.26. The company has a quick ratio of 2.92, a current ratio of 3.90 and a debt-to-equity ratio of 0.37.

Neogen (NASDAQ:NEOG – Get Free Report) last issued its quarterly earnings results on Tuesday, October 6th. The company reported $0.08 earnings per share for the quarter, beating analysts’ consensus estimates of $0.05 by $0.03. Neogen had a positive return on equity of 3.29% and a negative net margin of 6.35%. The business had revenue of $222.80 million for the quarter, compared to the consensus estimate of $208.18 million. During the same quarter in the previous year, the company posted $0.04 earnings per share. Neogen’s revenue for the quarter was up 6.5% compared to the same quarter last year. Equities analysts forecast that Neogen will post 0.27 EPS for the current fiscal year.

Institutional Investors Weigh In On Neogen

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC grew its stake in Neogen by 4.9% in the third quarter. GAMMA Investing LLC now owns 32,078 shares of the company’s stock valued at $411,000 after purchasing an additional 1,500 shares in the last quarter. Farther Finance Advisors LLC increased its position in Neogen by 76.1% in the 3rd quarter. Farther Finance Advisors LLC now owns 2,184 shares of the company’s stock worth $28,000 after purchasing an additional 944 shares during the last quarter. Plan A Wealth LLC acquired a new position in Neogen in the 3rd quarter worth about $133,000. Sequoia Financial Advisors LLC acquired a new position in Neogen in the 2nd quarter worth about $94,000. Finally, Integrated Wealth Concepts LLC acquired a new position in Neogen in the 2nd quarter worth about $73,000. Hedge funds and other institutional investors own 96.73% of the company’s stock.

Key Headlines Impacting Neogen

Here are the key news stories impacting Neogen this week:

  • Positive Sentiment: Strong quarterly results and higher guidance: Neogen reported fiscal first-quarter revenue of $222.8 million, up 6.5% year over year and above the $208.2 million consensus estimate. Adjusted earnings of $0.08 per share exceeded expectations by $0.03. Management also raised its fiscal 2027 outlook, supporting the recent increase in the stock. Neogen Q1 Revenue Rises 6.5%; Raises FY27 Outlook
  • Positive Sentiment: Encouraging long-term targets: At its 2026 Investor Day, Neogen outlined plans for sustained growth, greater research and development investment, and expansion toward a 30% EBITDA margin by fiscal 2031. The focus on recurring food-safety demand and innovation strengthens the long-term investment thesis, although execution will be important. Neogen Outlines Strategy for Growth, Innovation and Margin Expansion
  • Positive Sentiment: Analyst and industry support: Coverage has highlighted Neogen as a medical-products company positioned to benefit from favorable industry trends, while commentary on the earnings call described management as confident about its growth path. Medical Product Stocks Positioned to Ride on Industry Tailwinds
  • Neutral Sentiment: Short-interest data is inconsistent: A report described a significant increase in short interest but listed total short interest of zero shares and a 0.0-day short ratio. This suggests no meaningful short-selling pressure, though the data should be treated cautiously.
  • Negative Sentiment: FDA and legal overhang: Reports of an FDA warning related to a contaminated veterinary product could create compliance, reputation, or remediation costs. Separately, Pomerantz LLP announced an investigation into potential investor claims, adding headline and litigation risk. Neogen Received an FDA Warning

Neogen Company Profile

(Get Free Report)

Neogen Corporation is a global provider of food safety and animal safety products and services. The company develops diagnostic tests, laboratory products, and related solutions that help customers detect foodborne pathogens, allergens, toxins, residues, and other contaminants throughout the food production process.

Its food safety portfolio includes test kits, culture media, molecular testing systems, sanitation monitoring products, and laboratory supplies used by food manufacturers, processors, retailers, and regulatory organizations.

Further Reading